Ratlarda Sugammadex ve Rocuronium Kombinasyonunun Kraniyal Nörotoksisite Üzerine Etkisi: Deneysel Çalışma

Sugammadeks klinik anestezi uygulamalarında sıklıkla kullanılır. Sugammadeksin nörotoksik etkiye sahip olup olmadığını belirlemek için, beyin ve serebellum dokularının histopatolojik değerlendirmesi ve antioksidan durumu araştırıldı. Otuz iki erişkin sprague dawley sıçanı dört gruba ayrıldı. Purin Kontrol Grubuna (Grup 1, n=8) işlem yapılmadı. Kontrol grubuna (Grup 2, n=8) 16 mg/kg serum fizyolojik verildi. Sugammadex grubuna (Grup 3, n=8) 16 mg/kg sugammadex ve sugammadex+rocuronium grubuna (Grup 4, n=8) 16 mg/kg sugammadeks ve 1 mg/kg rokuronyum verildi. İlaç uygulamalarından sonra beyin ve beyincik dokuları histolojik ve oksidadif hasar açısından biyokimyasal olarak değerlendirildi. Beyin ve beyincik dokusunun genel yapısı tüm gruplarda normaldi. Katmanların ve içerdiği nöronların görüntüleri normaldi. Patolojik bulgu bulunamadı. Gruplar arasında sıçan beyninde glutatyon enzim aktivite düzeyleri (GSH-Px) ve malondialdehit (MDA) düzeyleri açısından istatistiksel olarak anlamlı bir fark yoktu. Serebellum dokularında GSH-Px ve MDA düzeyleri sugammadeks ve sugammadeks+rocuronium grubunda hafif bir artış gösterdi. Bu artışlar istatistiksel olarak anlamlıydı. Ancak bu artış, beyincik dokusunda histopatolojik hasara neden olmadı. Çalışma, sugammadeksin sıçanlarda rocuronyum etkisinin tersine çevrilmesinde güvenli olduğunu göstermektedir. Çalışmada kullanılan doz aralıklarında sugammadeks sıçan beyni ve beyincik dokularında olumsuz etki oluşturmamıştır.

Effect of Sugammadex and Rocuronium Combination on Cranial Neurotoxicity in Rats: Experimental Study

Sugammadex is frequently used in clinical anesthetic practice. In order to determine whether sugammadex has neurotoxic effect,histopathological evaluation and antioxidant status of brain and cerebellum tissues were investigated. Thirty-two adult sprague dawleyrats were divided into four groups. Purine Control Group (Group 1, n=8) had no action. The control group (Group 2, n=8) received 16 mg/kg serum physiologic, the sugammadex group (Group 3, n=8) received 16 mg/kg sugammadex and the sugammadex+rocuronium group(Group 4, n=8) received 16 mg/kg sugammadex and 1 mg/kg rocuronium. After drug administration, brain and cerebellum tissues wereevaluated histological and biochemically for and oxidative damage. The overall structure of the brain and cerebellum tissues were normalin all groups. Images of the layers and the neurons contained there in were normal. No pathological findings were found. There had nostatistically significant diffrence between the groups in terms of glutathione enzyme activity levels (GSH-Px) and the malondialdehyde(MDA) levels in rat brain. GSH-Px and MDA levels had a slight increase in sugammadex and sugammadex+rocuronium group in cerebellumtissues. These increases were statistically significant. But this increase did not cause any histopathological damage to the cerebellum tissue.The study demonstrates that sugammadex is safe for reversal of rocuronium effcts in rats. Sugammadex in the dose ranges used in thestudies, did not produce adverse effcts in rats brain and cerebellum tissues.

PDF

___

1. Lien CA: Development and potential clinical impairment of ultrashort-acting neuromuscular blocking agents. Br J Anaesth, 107 (1): i60-i71, 2011. DOI: 10.1093/bja/aer341
2. de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LHDJ: Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: Reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth, 96 (2): 201-206, 2006. DOI: 10.1093/bja/aei306
3. Türk R, Kaya S, Dönmez İ, Özaydın İ, Merhan O, Yayla S, Ermutlu CŞ, Kaçar C, Aydın U, Aksoy Ö, Hüseyinoğlu Ü: The effct of rocuronium and sugammadex on progesterone levels in pregnant rabbits under general anesthesia. Kafkas Univ Vet Fak Derg, 25 (2): 179-184, 2019. DOI: 10.9775/kvfd.2018.20609
4. Naguib M: Sugammadex: Another milestone in clinical neuromuscular pharmacology. Anesth Analg, 104 (3): 575-581, 2007. DOI: 10.1213/01. ane.0000244594.63318.fc
5. Hristovska AM, Duch P, Allingstrup M, Afshari A: Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev, 8:CD012763, 2017. DOI: 10.1002/14651858.CD012763
6. Cammu G, De Kam PJ, Demeyer I, Decoopman M, Peeters PA, Smeets JM, Foubert L: Safety and toler-ability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth, 100 (3): 373-379, 2008. DOI: 10.1093/bja/aem402
7. Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS: Reversal of profound, highdose rocuronium-induced neuromuscular blockade by sugammadex at two diffrent time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology, 109 (2): 188-197, 2008. DOI: 10.1097/ALN.0b013e31817f5bc7
8. Marrocco I, Altieri F, Peluso I: Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxid Med Cell Longev, 2017:6501046, 2017. DOI: 10.1155/2017/6501046
9. Srivastava KK, Kumar R: Stress, oxidative ınjury and disease. Indian J Clin Biochem, 30 (1): 3-10, 2015. DOI: 10.1007/s12291-014-0441-5
10. Mitchell C, Lobaz S: An overviev of sugammadex. Anaesthesia Tutorial of the Week. 1-6, 2016.
11. Palanca JM, Aguirre-Rueda D, Granell MV, Aldasoro M, Garcia A, Iradi A, Obrador E, Mauricio MD, Vila J, Gil-Bisquert A, Valles SL: Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. Int J Med Sci, 10 (10): 1278-1285, 2013. DOI: 10.7150/ijms.6254
12. Uludağ Ö: Hayvan deneyi çalışmalarında etik kuralların tarihçesi ve önemi. Adıyaman Üniv Sağlık Bil Derg, 5 (1): 1401-1413, 2019. DOI: 10.30569/adiyamansaglik.482098
13. Uchiyama M, Mihara M: Determination of malonaldehyde precursor in tissue by TBA test. Anal Biochem, 86 (1): 271-278, 1978. DOI: 10.1016/0003- 2697(78)90342-1
14. Elman GL: Tissue sulphydryl groups. Arch Biochem Biophys, 82 (1): 70- 77, 1959. DOI: 10.1016/0003-9861(59)90090-6
15. Kovac AL: Sugammadex: The first selective binding reversal agent for neuromuscular block. J Clin Anesth, 21 (6): 444-453, 2009. DOI: 10.1016/j. jclinane.2009.05.002
16. Rufini S, Grossi D, Luly P, Tancredi V, Frank C, D’Arcangelo G: Cholesterol depletion inhibits electrophysiological changes induced by anoxia in CA1 region of rat hippocampal slices. Brain Res, 1298, 178-185, 2009. DOI: 10.1016/j.brainres.2009.08.037
17. Frank C, Rufini S, Tancredi V, Forcina R, Grossi D, D’Arcangelo G: Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. Exp Neurol, 212 (2): 407-414, 2008. DOI: 10.1016/j.expneurol.2008.04.019
18. Abulrob A, Tauskela JS, Mealing G, Brunette E, Faid K, Stanimirovic D: Protection by cholesterol-extracting cyclodextrins: A role for N-methylD-aspartate receptor redistribution. J Neurochem, 92 (6): 1477-1486, 2005. DOI: 10.1111/j.1471-4159.2005.03001.x
19. Rivers JR, Maggo SDS, Ashton JC: Neuroprotective effct of hydroxypropyl-b-cyclodextrin in hypoxia-ischemia. Neuroreport, 23 (3): 134-138, 2012. DOI: 10.1097/WNR.0b013e32834ee47c
20. Ozbilgin S, Yılmaz O, Ergur BU, Hancı V, Ozbal S, Yurtlu S, Gunenc SF, Kuvaki B, Kucuk BA, Sisman AR: Effctiveness of sugammadex for cerebral ischemia/reperfusion injury. Kaohsiung J Med Sci, 32 (6): 292-301, 2016. DOI: 10.1016/j.kjms.2016.05.002
21. Baykal M, Gökmen N, Doğan A, Erbayraktar S, Yılmaz O, Ocmen E, Erdost HA, Arkan A: The effcts of intra-cerebroventricular administered rocuronium on the central nervous system of rats and determination of its epileptic seizure-inducing dose. Braz J Anesthesiol, 67 (1): 1-5, 2017. DOI: 10.1016/j.bjane.2015.02.010
22. Savarese JJ, Caldwel JE, Lien CA, Miller RD: Pharmacology of muscle relaxants and their antagonists. In, Miller RD (Ed): Anesthesia. 5 th ed., 412-490, Churchill Livingstone, Philadelphia, 2000.
23. Lobaz S, Clymer M, Sammut M: Safety and efficacy of sugammadex for neuromuscular blockade reversal. Clin Med Insights Ther, 6 (2): 1-14, 2014. DOI: 10.4137/CMT.S10241
24. Aldasoro M, Jorda A, Aldasoro C, Marchio P, Guerra-Ojeda S, Gimeno-Raga M, Mauricio MD, Iradi A, Obrador E, Vila J, Valles SL: Neuronal effcts of sugammadex in combination with rocuronium or vecuronium. Int J Med Sci, 14 (3): 224-230, 2017. DOI: 10.7150/ijms.17545
25. Guang H, Ji L: Proprioceptive recognition with artificial neural networks based on organizations of spinocerebellar tract and cerebellum. Int J Neural Syst, 9:1850056, 2018. DOI: 10.1142/S0129065718500569